Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study

被引：7

作者：

Grewal, Ramandip ^{[1
,2
,3
]}

Buchan, Sarah A. ^{[1
,2
,3
,4
]}

Nguyen, Lena ^{[4
]}

Nasreen, Sharifa ^{[2
,4
]}

Austin, Peter C. ^{[4
,5
]}

Brown, Kevin A. ^{[1
,2
,4
]}

Gubbay, Jonathan ^{[1
,6
]}

Lee, Nelson ^{[2
,7
]}

Schwartz, Kevin L. ^{[1
,2
,4
]}

Tadrous, Mina ^{[8
]}

Wilson, Kumanan ^{[9
,10
,11
]}

Wilson, Sarah E. ^{[1
,2
,3
,4
]}

Kwong, Jeffrey C. ^{[1
,2
,3
,4
,12
,13
]}

机构：

[1] Publ Hlth Ontario, Toronto, ON, Canada

[2] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada

[3] Univ Toronto, Ctr Vaccine Preventable Dis, Toronto, ON, Canada

[4] ICES, Toronto, ON, Canada

[5] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada

[6] British Columbia Childrens & Womens Hlth Ctr, Dept Pathol & Lab Med, Vancouver, BC, Canada

[7] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada

[8] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada

[9] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[10] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada

[11] Bruyere Res Inst, Ottawa, ON, Canada

[12] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada

[13] Univ Hlth Network, Toronto Western Family Hlth Team, Toronto, ON, Canada

来源：

JOURNAL OF INFECTIOUS DISEASES | 2024年 / 229卷 / 02期

基金：

加拿大健康研究院;

关键词：

bivalent; COVID-19; mRNA; vaccine effectiveness; Omicron;

D O I：

10.1093/infdis/jiad419

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged >= 50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines. Shortly after bivalent mRNA COVID-19 vaccines were introduced, monovalent and bivalent booster doses provided similar strong initial protection against severe outcomes among Ontario community-dwelling adults aged >= 50 years. Uncertainty remains around waning of protection.

引用

页码：394 / 397

页数：4

共 29 条

[21] Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study
Jia, Siyue
Yin, Zundong
Pan, Hongxing
Wang, Fuzhen
Liu, Xiaoqiang
Wang, Qing
Zhang, Li
Tang, Jihai
Yang, Hao
Du, Jiangbo
Wang, Zhiguo
Jin, Pengfei
Peng, Zhihang
Tang, Rong
Kang, Guodong
Wang, Xuewen
Li, Simin
Wang, Weixiao
Li, Jingxin
Shen, Hongbing
Zhu, Fengcai
[J]. EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
[22] Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021
Fabiani, Massimo
Puopolo, Maria
Filia, Antonietta
Sacco, Chiara
Mateo-Urdiales, Alberto
Alegiani, Stefania Spila
Del Manso, Martina
D'Ancona, Fortunato
Vescio, Fenicia
Bressi, Marco
Petrone, Daniele
Spuri, Matteo
Rota, Maria Cristina
Massari, Marco
Da Cas, Roberto
Morciano, Cristina
Stefanelli, Paola
Bella, Antonino
Tallon, Marco
Proietti, Valeria
Siddu, Andrea
Battilomo, Serena
Palamara, Anna Teresa
Popoli, Patrizia
Brusaferro, Silvio
Rezza, Giovanni
Riccardo, Flavia
Ippolito, Francesca Menniti
Pezzotti, Patrizio
[J]. EXPERT REVIEW OF VACCINES, 2022, 21 (07) : 975 - 982
[23] Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection
Wong, Carlos K. H.
Lau, Kristy T. K.
Au, Ivan C. H.
Lau, Eric H. Y.
Cowling, Benjamin J.
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (03)
[24] Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Terada, Mayumi
Masuda, Shingo
Osawa, Ryosuke
Hosokawa, Naoto
Nakashima, Kei
Kamura, Hiroshi
Imura, Haruki
Inoue, Hiroki
Matsuzaka, Suguru
Sugimoto, Yukihiro
Kuwamitsu, Osamu
Motohashi, Iori
Morikawa, Toru
Oda, Rentaro
Hoshina, Yuiko
Matono, Takashi
Teshigahara, Osamu
Sando, Eiichiro
Asami, Sadaharu
Kudo, Satoshi
Akizuki, Noboru
Muto, Yoshikazu
Hayakawa, Tomoichiro
Kishaba, Tomoo
Ohara, Yasuji
Kubo, Yoshinao
Suzuki, Motoi
Morimoto, Konosuke
[J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 213 - 225
[25] Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study
Wang, Qing
Xu, Jiawei
Liu, Yu
Li, Jianqiao
[J]. MEDICINE, 2024, 103 (42) : e40075
[26] Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study
Fabiani, Massimo
Mateo-Urdiales, Alberto
Sacco, Chiara
Rota, Maria Cristina
Petrone, Daniele
Bressi, Marco
Del Manso, Martina
Siddu, Andrea
Proietti, Valeria
Battilomo, Serena
Menniti-Ippolito, Francesca
Popoli, Patrizia
Bella, Antonino
Riccardo, Flavia
Palamara, Anna Teresa
Rezza, Giovanni
Brusaferro, Silvio
Pezzotti, Patrizio
[J]. VACCINE, 2023, 41 (01) : 76 - 84
[27] Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020-17 May 2021): a population-level observational study
Tessier, Elise
Rai, Yuma
Clarke, Eleanor
Lakhani, Anissa
Tsang, Camille
Makwana, Ashley
Heard, Heather
Rickeard, Tim
Lakhani, Shreya
Roy, Partho
Edelstein, Michael
Ramsay, Mary
Lopez-Bernal, Jamie
White, Joanne
Andrews, Nick
Campbell, Colin N. J.
Stowe, Julia
[J]. BMJ OPEN, 2022, 12 (03):
[28] Real-world effectiveness of original BNT162b2 mRNA COVID-19 against symptomatic Omicron infection among children 5-11 years of age in Brazil: A prospective test-negative design study
Rodrigues, Cristina de Oliveira
Spinardi, Julia
Rosa, Regis Goulart
Falavigna, Maicon
de Souza, Emanuel Maltempi
Manfio, Joselia Larger
Souza, Ana Paula de
de Araujo, Cintia Laura Pereira
Cohen, Mirian
Barbosa, Gynara Rezende Gonzalez do Valle
Silva, Fernanda Kelly Romeiro
Sganzerla, Daniel
da Silva, Mariana Motta Dias
Ferreira, Diogo
Kunkel, Nicolas Taciano
Camargo, Nathan Iori
Sarturi, Jean Carlos
Guilhem, Marcia Cristina
de Oliveira, Jaqueline Carvalho
Lopes, Caroline Cardoso
Widmar, Fernanda
Barufi, Leticia Killes
da Silva, Gabrielle Nunes
Gradia, Daniela Fiori
Brandalize, Ana Paula Carneiro
Royer, Carla Adriane
Luiz, Rafael Messias
Baura, Valter Antonio
Abreu, Hellen
Poitevin, Carolina Gracia
Kucharski, Gabriela Almeida
Pedrotti, Fernando
Valluri, Srinivas Rao
Srivastava, Amit
Juliao, Viviane Wal
Melone, Olga Chameh
Allen, Kristen E.
Kyaw, Moe H.
Castillo, Graciela del Carmen Morales
Mclaughlin, John
[J]. IMMUNOLOGY LETTERS, 2024, 269
[29] Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Antunes, Liliana
Rojas-Castro, Madelyn
Lozano, Marcos
Martinez-Baz, Ivan
Leroux-Roels, Isabel
Borg, Maria-Louise
Oroszi, Beatrix
Fitzgerald, Margaret
Duerrwald, Ralf
Jancoriene, Ligita
Machado, Ausenda
Petrovic, Goranka
Lazar, Mihaela
Souckova, Lenka
Bacci, Sabrina
Howard, Jennifer
Verdasca, Nuno
Basile, Luca
Castilla, Jesus
Ternest, Silke
Dziugyte, Ausra
Turi, Gergo
Duffy, Roisin
Hackmann, Carolin
Kuliese, Monika
Gomez, Veronica
Makaric, Zvjezdana Lovric
Marin, Alexandru
Husa, Petr
Nicolay, Nathalie
Rose, Angela M. C.
VEBIS SARI VE network team
[J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2025, 19 (03)

← 1 2 3 →